Welcome to our dedicated page for Inmed Pharmaceuticals news (Ticker: INM), a resource for investors and traders seeking the latest updates and insights on Inmed Pharmaceuticals stock.
InMed Pharmaceuticals Inc. reports developments as a pharmaceutical company developing proprietary small-molecule drug candidates for diseases with high unmet medical needs. Its pipeline targets CB1 and CB2 receptors and includes INM-901 for Alzheimer's disease, along with ocular and dermatological programs.
Recurring updates cover financial results, business progress, preclinical and regulatory disclosures, shareholder voting matters, capital actions, Nasdaq listing compliance, and changes affecting BayMedica, its wholly owned subsidiary historically associated with rare cannabinoid commercial activities.
InMed (NASDAQ:INM) agreed to an all-stock merger with privately held Mentari Therapeutics, creating a Nasdaq-listed company focused on migraine prevention.
A concurrent oversubscribed US$290 million private placement is expected to fund operations through 2028, supporting development of lead antibodies MT-001 and MT-002 with key clinical readouts targeted for 2027–2028.
InMed Pharmaceuticals (NASDAQ: INM) entered a definitive all-stock merger agreement with privately held Mentari Therapeutics to advance migraine prevention therapies. The combined company will operate as Mentari Therapeutics and trade on Nasdaq under a new ticker.
A concurrent oversubscribed US$290 million private placement is expected to fund operations through 2028, supporting first-in-human regulatory filings for lead candidates MT-001 (anti-PACAP) in mid-2026 and MT-002 (anti-CGRP x PACAP bispecific) in Q1 2027, with key clinical readouts targeted for 2027–2028.
InMed Pharmaceuticals (NASDAQ: INM) announced an amendment to certain preferred investment options held by Armistice Capital Master Fund. These options, originally dated October 26, 2023, allow subscription for up to 278,761 common shares.
The exercise price was reduced from $16.60 per share to $0.80 per share. The options were issued via private placement under Section 4(a)(2) of the Securities Act and Regulation D. There is no assurance that any options will be exercised.
InMed (NASDAQ: INM) reported third quarter fiscal 2026 results for the period ended March 31, 2026. The company highlighted new preclinical INM-901 data in human 3D brain organoids showing dose-dependent reductions in IL-6 and IL-8 and alignment with prior in vivo/ex vivo results. The board approved winding down BayMedica commercial operations; discontinued operations generated $0.7M during the quarter. Continuing operations reported a quarterly net loss of $3.0M, R&D of $1.0M, and cash, cash equivalents and short-term investments of $5.2M as of March 31, 2026.
InMed Pharmaceuticals (NASDAQ: INM) amended previously issued preferred investment options with Sabby Volatility Warrant Master Fund and affiliates of H.C. Wainwright to change exercise prices to $0.80 per share. The amendments apply to rights to subscribe for up to 2,151,478 shares (Sabby) and 153,236 shares (Wainwright) on a post-consolidation basis. The options were issued in private placements under Section 4(a)(2) and Regulation D. No assurance any options will be exercised.
InMed Pharmaceuticals (NASDAQ: INM) received a Nasdaq notice dated March 27, 2026 that the closing bid price was below the $1.00 minimum during the February 11, 2026–March 26, 2026 period.
The company has a 180-calendar day cure period to regain compliance by achieving a $1.00 closing bid for at least 10 consecutive business days; trading will continue under the symbol INM.
InMed Pharmaceuticals (NASDAQ: INM) reported preclinical data showing INM-901 reduced neuroinflammation in two human 3D brain organoid models, including a Stem Pharm Alzheimer's disease model.
Findings showed dose-dependent reductions in IL-6 and IL-8, aligned with prior in vivo and ex vivo results, and support a planned pre-IND meeting in Q3 2026 and a targeted IND/Phase 1 start in 2027.
InMed (NASDAQ: INM) outlines 2026 pharmaceutical development priorities, focusing on advancing INM-901 toward a pre-IND meeting in Q3 2026 and IND-enabling studies with a target to submit an IND and initiate a Phase 1 Alzheimer’s trial in 2027. Key preclinical findings show anti-neuroinflammatory effects, neuroprotection, neuritogenesis, behavioral gains, and oral bioavailability in large animals. The company also plans a pre-IND meeting for INM-089 in Q4 2026 and continues formulation, scale-up, and regulatory planning for both programs.
InMed Pharmaceuticals (NASDAQ: INM) announced BayMedica LLC will wind down its commercial operations due to regulatory uncertainty from H.R. 5371, which could prohibit parts of BayMedica's cannabinoid commercial business if effective November 12, 2026. BayMedica expects to substantially complete the exit before June 30, 2026.
The company will focus exclusively on advancing its pharmaceutical pipeline, notably INM-901 for Alzheimer’s disease and INM-089 for dry age-related macular degeneration, toward IND filings and initial human trials. Estimated one-time employee-related costs total approximately $550,000 plus $120,000 of additional expenditures through fiscal year end.
InMed (NASDAQ: INM) reported Q2 FY2026 results for the quarter ended December 31, 2025 and provided a pipeline update. Key developments: INM-901 completed large-animal oral PK studies with robust bioavailability and no adverse neural effects; INM-089 showed functional improvements in dry AMD models. Financials: cash of $7.0M, Q2 net loss of $2.03M, BayMedica revenue down 26% YoY to $0.8M. The company expects cash to fund operations into Q4 calendar 2026 and flagged material legislative risk from H.R. 5371 affecting BayMedica.